Neuromuscular Blocking Agents

Phase 3Small molecule

UUniversity of Maryland, Baltimore

Neuromuscular Blocking Agents is one of 2 small molecule programs targeting Neostigmine. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

NeostigmineNot yet recruiting

DistressActive, not recruiting

NeostigminePhase 3

Not yet recruiting

DistressPhase 2

Active, not recruiting

Competition

Competitive Landscape

2 competitors in Neostigmine

#DrugCompanyPhaseTrials

Neuromuscular Blocking Agents

UUniversity of Maryland, Baltimore

Phase 3

1 2

Sugammadex Sodium

KKorea University Anam Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Active, not recruiting

Distress

NCT04545424

Clinical

Trials by Indication[1]

Neuromuscular Blockade2 trials

Paediatric Ards Neuromuscular Blockade Study

Terminated·UUniversity Medical Center Groningen·Phase 4·NCT02902055·3 enrolled

Neuromuscular Blockade in the Intentive Care Unit, an Observational Study.

Completed·FFrench Society for Intensive Care··NCT04028362·282 enrolled

Hypothermia1 trial

Pilot RCT of Therapeutic Hypothermia Plus Neuromuscular Blockade in COVID-19 Patients With ARDS

Withdrawn·UUniversity of Maryland, Baltimore·Phase 2·NCT03376854

Complication1 trial

Avoiding Neuromuscular Blockers to Reduce Complications

Terminated·—·Phase 4·NCT03962725·3 enrolled

Acute Respiratory Distress Syndrome1 trial

Individualized Positive End-expiratory Pressure Guided by End-expiratory Lung Volume in the Acute Respiratory Distress Syndrome

Terminated·FFondazione Policlinico Universitario Agostino Gemelli IRCCS·Phase 3·NCT04012073·18 enrolled

Neostigmine1 trial

Comparison of Sugammadex and Neostigmine During PACU Stay

Not yet recruiting·UUniversity of South Florida·Phase 3·NCT04096144·50 enrolled

1 more indication

Distress1 trial

Cooling to Help Injured Lungs (CHILL) Phase IIB Randomized Control Trial of Therapeutic Hypothermia in Patients With ARDS

Active, not recruiting·UUniversity of Maryland, Baltimore·Phase 2·NCT04545424·340 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Neuromuscular Blocking Agents. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Neuromuscular Blocking Agents compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Neuromuscular Blocking Agents. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Maryland, Baltimore company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity of Maryland, Baltimore

Neuromuscular Blocking Agents

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Neuromuscular Blockade2 trials

Hypothermia1 trial

Complication1 trial

Acute Respiratory Distress Syndrome1 trial

Neostigmine1 trial

Distress1 trial

References

Drug Info

Quick Facts

Related News